Ocumension Therapeutics' OT-702 gets China marketing approval

Ocumension Therapeutics announced that its Aflibercept Intravitreous Injection biosimilar, OT-702, has received marketing approval from China's National Medical Products Administration (NMPA). This approval targets the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.

OT-702, a biosimilar to EYLEA®, was developed in partnership with Shandong Boan Biotechnology Co., Ltd. Ocumension Therapeutics holds the exclusive right to promote and commercialize the product in China. The company also noted that, based on Chinese technical guidelines, OT-702 is eligible to apply for approval for all indications approved for EYLEA® in China.